Buffington Mohr McNeal Sells 1,000 Shares of Teleflex Incorporated (NYSE:TFX)

Buffington Mohr McNeal lowered its stake in shares of Teleflex Incorporated (NYSE:TFX) by 22.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,380 shares of the medical technology company’s stock after selling 1,000 shares during the quarter. Buffington Mohr McNeal’s holdings in Teleflex were worth $602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TFX. Simplify Asset Management Inc. acquired a new position in shares of Teleflex during the third quarter worth $4,800,000. JPMorgan Chase & Co. increased its position in Teleflex by 14.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company’s stock valued at $38,374,000 after buying an additional 19,466 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Teleflex by 19.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 484 shares of the medical technology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter. LGT Capital Partners LTD. raised its stake in Teleflex by 4.2% in the third quarter. LGT Capital Partners LTD. now owns 231,685 shares of the medical technology company’s stock valued at $57,300,000 after buying an additional 9,411 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Teleflex by 41.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 24,301 shares of the medical technology company’s stock worth $6,010,000 after acquiring an additional 7,132 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

NYSE TFX opened at $183.81 on Tuesday. Teleflex Incorporated has a fifty-two week low of $171.69 and a fifty-two week high of $256.85. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The firm has a market capitalization of $8.54 billion, a P/E ratio of 36.54, a PEG ratio of 1.79 and a beta of 1.16. The stock has a 50-day simple moving average of $182.85 and a two-hundred day simple moving average of $214.30.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping the consensus estimate of $3.38 by $0.11. The business had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.64 EPS. On average, equities analysts forecast that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were issued a $0.34 dividend. The ex-dividend date was Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.74%. Teleflex’s payout ratio is 27.04%.

Analysts Set New Price Targets

TFX has been the topic of several recent analyst reports. Mizuho cut their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Royal Bank of Canada lowered their price target on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial reduced their price objective on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and a consensus price target of $252.50.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.